ONTRANS: Oral Nicotinamide for skin cancer chemoprevention after Transplant [ 2016 - 2019 ]

Research Grant

Researchers: Prof Diona Damian (Principal investigator) ,  A/Pr Pablo Fernandez Peñas ,  Dr Andrew Martin ,  Prof Gary Halliday ,  Prof Josette Eris

Brief description The skin’s immune system is a key defence against skin cancer. Transplant recipients, who are chronically and profoundly immune suppressed to prevent rejection, have a 50-80 fold increase in skin cancer risk. Nicotinamide (vitamin B3) reduced skin cancer in our recent Phase 3 trial in immune competent individuals. A pilot study in renal transplant patients showed similar results. This project will determine at the Phase 3 level whether nicotinamide reduces skin cancers after kidney transplant.

Funding Amount $AUD 644,582.99

Funding Scheme Project Grants

Notes Standard Project Grant